Literature DB >> 32804079

Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.

Lu Lv1,2, Peihao Chen2,3, Longzhi Cao2,4, Yamei Li2,4, Zhi Zeng2,4, Yue Cui1,2, Qingcui Wu2, Jiaojiao Li2, Jian-Hua Wang2, Meng-Qiu Dong2,5, Xiangbing Qi2,5, Ting Han2,4,5.   

Abstract

Molecular-glue degraders mediate interactions between target proteins and components of the ubiquitin-proteasome system to cause selective protein degradation. Here, we report a new molecular glue HQ461 discovered by high-throughput screening. Using loss-of-function and gain-of-function genetic screening in human cancer cells followed by biochemical reconstitution, we show that HQ461 acts by promoting an interaction between CDK12 and DDB1-CUL4-RBX1 E3 ubiquitin ligase, leading to polyubiquitination and degradation of CDK12-interacting protein Cyclin K (CCNK). Degradation of CCNK mediated by HQ461 compromised CDK12 function, leading to reduced phosphorylation of a CDK12 substrate, downregulation of DNA damage response genes, and cell death. Structure-activity relationship analysis of HQ461 revealed the importance of a 5-methylthiazol-2-amine pharmacophore and resulted in an HQ461 derivate with improved potency. Our studies reveal a new molecular glue that recruits its target protein directly to DDB1 to bypass the requirement of a substrate-specific receptor, presenting a new strategy for targeted protein degradation.
© 2020, Lv et al.

Entities:  

Keywords:  CDK12/CCNK; biochemistry; chemical biology; human; molecular glue; target identification; targeted protein degradation

Mesh:

Substances:

Year:  2020        PMID: 32804079      PMCID: PMC7462607          DOI: 10.7554/eLife.59994

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  48 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.

Authors:  Xinlin Du; Oleg A Volkov; Robert M Czerwinski; HuiLing Tan; Carlos Huerta; Emily R Morton; Jim P Rizzi; Paul M Wehn; Rui Xu; Deepak Nijhawan; Eli M Wallace
Journal:  Structure       Date:  2019-11-05       Impact factor: 5.006

3.  Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.

Authors:  Julia Joung; Silvana Konermann; Jonathan S Gootenberg; Omar O Abudayyeh; Randall J Platt; Mark D Brigham; Neville E Sanjana; Feng Zhang
Journal:  Nat Protoc       Date:  2017-03-23       Impact factor: 13.491

4.  EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.

Authors:  Amanda Balboni Iniguez; Björn Stolte; Emily Jue Wang; Amy Saur Conway; Gabriela Alexe; Neekesh V Dharia; Nicholas Kwiatkowski; Tinghu Zhang; Brian J Abraham; Jaume Mora; Peter Kalev; Alan Leggett; Dipanjan Chowdhury; Cyril H Benes; Richard A Young; Nathanael S Gray; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2018-01-18       Impact factor: 31.743

5.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

6.  Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.

Authors:  S-W Grace Cheng; Michael A Kuzyk; Annie Moradian; Taka-Aki Ichu; Vicky C-D Chang; Jerry F Tien; Sarah E Vollett; Malachi Griffith; Marco A Marra; Gregg B Morin
Journal:  Mol Cell Biol       Date:  2012-09-17       Impact factor: 4.272

7.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

8.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

9.  Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.

Authors:  Tyler B Faust; Hojong Yoon; Radosław P Nowak; Katherine A Donovan; Zhengnian Li; Quan Cai; Nicholas A Eleuteri; Tinghu Zhang; Nathanael S Gray; Eric S Fischer
Journal:  Nat Chem Biol       Date:  2019-11-04       Impact factor: 15.040

10.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Authors:  Ilirjana Bajrami; Jessica R Frankum; Asha Konde; Rowan E Miller; Farah L Rehman; Rachel Brough; James Campbell; David Sims; Rumana Rafiq; Sean Hooper; Lina Chen; Iwanka Kozarewa; Ioannis Assiotis; Kerry Fenwick; Rachael Natrajan; Christopher J Lord; Alan Ashworth
Journal:  Cancer Res       Date:  2013-11-15       Impact factor: 12.701

View more
  20 in total

1.  Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras.

Authors:  He Chen; Jing Liu; H Ümit Kaniskan; Wenyi Wei; Jian Jin
Journal:  J Med Chem       Date:  2021-08-11       Impact factor: 8.039

Review 2.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

3.  Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.

Authors:  Lu Lv; Peihao Chen; Longzhi Cao; Yamei Li; Zhi Zeng; Yue Cui; Qingcui Wu; Jiaojiao Li; Jian-Hua Wang; Meng-Qiu Dong; Xiangbing Qi; Ting Han
Journal:  Elife       Date:  2020-08-17       Impact factor: 8.140

Review 4.  Ubiquitin-dependent regulation of transcription in development and disease.

Authors:  Kevin G Mark; Michael Rape
Journal:  EMBO Rep       Date:  2021-03-28       Impact factor: 8.807

Review 5.  Decoding the messaging of the ubiquitin system using chemical and protein probes.

Authors:  Lukas T Henneberg; Brenda A Schulman
Journal:  Cell Chem Biol       Date:  2021-04-07       Impact factor: 8.116

Review 6.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

Review 7.  Ubiquitin ligases in cancer: Functions and clinical potentials.

Authors:  Shanshan Duan; Michele Pagano
Journal:  Cell Chem Biol       Date:  2021-05-10       Impact factor: 9.039

Review 8.  Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.

Authors:  Shanique Alabi; Craig Crews
Journal:  J Biol Chem       Date:  2021-04-08       Impact factor: 5.157

Review 9.  Cell cycle on the crossroad of tumorigenesis and cancer therapy.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Trends Cell Biol       Date:  2021-07-22       Impact factor: 20.808

Review 10.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.